Outcomes 48 weeks after switching from DTG/ABC/3TC or DTG+F/TAF to B/F/TAF

被引：0
|
作者：
Pozniak, A. [1 ]
Maggiolo, F. [2 ]
Podzamczer, D. [3 ]
Yazdanpanah, Y. [4 ]
Gupta, S. [5 ]
Esser, S. [6 ]
Mounzer, K. [7 ]
Grossberg, R. [8 ]
Post, F. [9 ]
Huang, H. [10 ]
Acosta, R. [10 ]
Baeten, J. [10 ]
Hindman, J. [10 ]
Martin, H. [10 ]
Orkin, C. [11 ]
机构：
[1] Chelsea & Westminster Hosp, London, England
[2] Azienda Osped Papa Giovanni XXIII, Bergamo, Italy
[3] Hosp Univ Bellvitge, Lhospitalet De Llobregat, Spain
[4] Hop Bichat Claude Bernard, AP HP, Paris, France
[5] Indiana Univ, Indianapolis, IN 46204 USA
[6] Univ Hosp Essen, Essen, Germany
[7] Univ Penn, Philadelphia FIGHT Perelman Sch Med, Philadelphia, PA 19104 USA
[8] Albert Einstein Coll Med, Bronx, NY 10467 USA
[9] Kings Coll Hosp NHS Fdn Trust, Kings Coll Hosp, London, England
[10] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA
[11] Queen Mary Univ London, London, England
来源：
HIV MEDICINE | 2021年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
PE2/68
引用
收藏
页码：125 / 125
页数：1
相关论文
共 50 条
  • [31] Detection of 12-month immunological changes in patients randomised to switch either to BIC/TAF/FTC or DTG/3TC (DEBATE study)
    Cossarizza, A.
    Mattioli, M.
    Paolini, A.
    Neroni, A.
    De Biasi, S.
    Lo Tartaro, D.
    Borella, R.
    Fidanza, L.
    Gibellini, L.
    Beghetto, B.
    Roncaglia, E.
    Nardini, G.
    Menozzi, M.
    Cuomo, G.
    Di Gaetano, M.
    Orlando, G.
    Borghi, V.
    Mussini, C.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 99 - 100
  • [32] Switching to DTG/3TC fixed-dose combination (FDC) is non-inferior to continuing a TAF-based regimen (TBR) in maintaining virologic suppression through 96 weeks (TANGO study)
    van Wyk, J.
    Ajana, F.
    Bisshop, F.
    De Wit, S.
    Osiyemi, O.
    Portilla, J.
    Routy, J.
    Wyen, C.
    Ait-Khaled, M.
    Nascimento, M.
    Pappa, K.
    Wang, R.
    Wright, J.
    Wynne, B.
    Aboud, M.
    Smith, K.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 14 - 15
  • [33] Week 48 results of a phase 3 randomised controlled trial of B/F/TAF vs. DTG plus F/TDF as initial treatment in adults with HIV/HBV coinfection (ALLIANCE)
    Avihingsanon, Anchalee
    Lu, Hongzhou
    Leong, Chee Loon
    Hung, Chien-Ching
    Koening, Ellen
    Kiertiburanakul, Sasisopin
    Lee, Man-Po
    Supparatpinyo, Khuanchai
    Zhang, Fujie
    Rahman, Sophia
    Brogan, Michelle D'Antoni
    Wang, Hongyuan
    Hindman, Jason
    Martin, Hal
    Mack, Frank
    Baeten, Jared
    HIV MEDICINE, 2023, 24 : 54 - 54
  • [34] Safety and efficacy of switching people with HIV to dual treatment with 3TC/DTG and RPV/DTG in real life: results from the SCOLTA cohort
    De Vito, A.
    Ricci, E.
    Orofino, G.
    Taramasso, L.
    Sarchi, E.
    Costa, C.
    Pellicano, G.
    Pagnucco, L.
    Menzaghi, B.
    De Socio, G.
    Celesia, B.
    Piconi, S.
    Maggi, P.
    Bonfanti, P.
    Madeddu, G.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 83 - 85
  • [35] Switching from a three-drug TAF-based regimen to a two-drug DTG/3TC FDC was not associated with a higher frequency of intermittent viraemia in suppressed patients in TANGO
    Wang, R.
    Horton, J.
    Wright, J.
    Razeek, R.
    Ait-Khaled, M.
    Nascimento, M. C.
    Underwood, M.
    van Wyk, J.
    HIV MEDICINE, 2020, 21 : 22 - 22
  • [36] Outcomes of participants switching from F/TDF to F/TAF for PrEP: week 48 results from the DISCOVER open label phase
    Spinner, C.
    Avery, A.
    Flamm, J. A.
    Crofoot, G.
    Brinson, C.
    Kronborg, G.
    DeJesus, E.
    Carter, C.
    Kintu, A.
    Shao, Y.
    Ebrahimi, R.
    Das, M.
    Baeten, J. M.
    Clarke, A.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2021, 24 : 29 - 29
  • [37] Switching to DTG/3TC is non-inferior to continuing current antiretroviral regimen at week 48: SALSA subgroup analyses
    Taylor, S.
    Andrade-Villanueva, J. F.
    Kaplan, R.
    Nahass, R.
    Hocqueloux, L.
    Scholten, S.
    Di Giambenedetto, S.
    Galera, C.
    Blair, L.
    Wynne, B.
    Oyee, J.
    Underwood, M.
    Curtis, L.
    Bontempo, G.
    van Wyk, J.
    HIV MEDICINE, 2021, 22 : 129 - 129
  • [38] Phase III randomized, controlled clinical trial of bictegravir coformulated with FTC/TAF in a fixed-dose combination (B/F/TAF) versus dolutegravir (DTG) plus F/TAF in treatment-naive HIV-1 positive adults: Week 96
    Stellbrink, H.
    Arribas, J.
    Stephens, J.
    Albrecht, H.
    Sax, P.
    Maggiolo, F.
    Creticos, C.
    Martorell, C.
    Wei, X.
    White, K.
    Collins, S.
    Cheng, A.
    Martin, H.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [39] Switching to dolutegravir/lamivudine (DTG/3TC) fixed-dose combination (FDC) is non-inferior to continuing a tenofovir alafenamide (TAF)-based regimen (TBR) in maintaining virological suppression through 96 weeks (TANGO study)
    Van Wyk, Jean
    Ajana, Faiza
    Bisshop, Fiona
    De Wit, Stephane
    Osiyemi, Olayemi
    Portilla, Joaquin
    Routy, Jean-Pierre
    Wyen, Christoph
    Ait-Khaled, Mounir
    Nascimento, Maria-Claudia
    Pappa, Keith A.
    Wang, Ruolan
    Wright, Jonathan
    Wynne, Brian
    Aboud, Michael
    Smith, Kimberly Y.
    HIV MEDICINE, 2021, 22 : 28 - 28
  • [40] Effectiveness of a dual therapy based on DTG/3TC on reduction of the viral reservoir, immune recovery and immune activation compared with a triple antiretroviral therapy based on DTG/TAF/ FTC in patients with HIV infection without prior treatment
    Saborido-Alconchel, Abraham
    Trujillo-Rodriguez, Maria
    Serna-Gallego, Ana
    Munoz-Muela, Esperanza
    Rivas-Jeremias, Inmaculada
    Alvarez-Rios, Ana
    Espinosa, Nuria
    Roca, Cristina
    Herrero, Marta
    Sotomayor, Cesar
    Gutierrez-Valencia, Alicia
    Lopez-Cortes, Luis Fernando
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 206 - 206
12345